Diagnosis: Non-Alcoholic Fatty Liver Disease (NAFLD)
When an abdominal ultrasound shows fatty liver (hepatic steatosis), the most likely diagnosis is Non-Alcoholic Fatty Liver Disease (NAFLD), provided you have excluded significant alcohol consumption and other secondary causes of hepatic fat accumulation 1, 2.
Diagnostic Approach
Initial Assessment Required
The finding of hepatic steatosis on ultrasound should trigger the following immediate actions:
Screen for alcohol use using standardized tools (Alcohol Use Disorders Identification Test) to exclude alcohol-related liver disease 2
Obtain focused history for:
- Metabolic risk factors (obesity, type 2 diabetes, dyslipidemia, hypertension)
- Detailed medication history (certain drugs can cause steatosis)
- Risk factors for viral hepatitis
Order basic laboratory tests:
- Complete metabolic panel (includes ALT, AST, albumin)
- Complete blood count (for platelet count)
- Hepatitis B and C serologies
- Consider additional tests to exclude rare causes (iron studies, ceruloplasmin, autoimmune markers)
Critical Caveat About Liver Enzymes
Do not rely on normal liver enzymes to exclude significant liver disease. Normal ALT occurs frequently in NAFLD patients, even those with advanced fibrosis or cirrhosis 1. In one study, ALT >2× upper limit of normal had only 50% sensitivity for NASH and 40% sensitivity for advanced fibrosis 1. The serum ALT typically falls as fibrosis progresses 1.
Immediate Next Step: Fibrosis Risk Stratification
The finding of steatosis on ultrasound should immediately prompt assessment for advanced liver fibrosis, as fibrosis stage is the key predictor of liver-related morbidity and mortality 1, 2.
Calculate FIB-4 Score
Use the FIB-4 index as your first-line fibrosis assessment tool (requires age, ALT, AST, platelet count) 2:
FIB-4 <1.3 (or <2.0 if age >65 years): Low risk for advanced fibrosis
- Reassure patient
- Repeat FIB-4 in 2-3 years
- Address metabolic risk factors
FIB-4 1.3-2.67: Indeterminate risk
- Perform second-tier testing (transient elastography or Enhanced Liver Fibrosis test)
- Consider hepatology referral
FIB-4 >2.67: High risk for advanced fibrosis
Important Limitations
- FIB-4 and NAFLD Fibrosis Score are not validated in patients <35 years old 1
- These scores are more accurate for distinguishing advanced fibrosis (F3-F4) and may miss some F2 patients initially, though these will be detected on subsequent assessments as they progress 2
Why This Matters for Outcomes
Patients with NAFLD and advanced fibrosis (stage 3-4) face significantly increased risk of:
- Hepatic decompensation
- Hepatocellular carcinoma
- Liver transplantation
- Liver-related death 1
Additionally, patients with hepatic steatosis are at substantially elevated cardiovascular and metabolic risk, independent of liver enzyme levels 3. Steatosis associates strongly with metabolic syndrome components and cardiovascular disease 3, 4.
Ultrasound Performance Characteristics
Ultrasound has high accuracy for detecting moderate-to-severe steatosis (>33% hepatic involvement) but suboptimal sensitivity for mild steatosis 5, 6. However, ultrasound cannot stage fibrosis or distinguish simple steatosis from steatohepatitis (NASH) 7, 8. For patients in high-risk groups (obesity, type 2 diabetes, metabolic syndrome), you can reasonably proceed directly to fibrosis risk stratification without requiring ultrasound confirmation of steatosis 2.
Common Pitfalls to Avoid
- Do not assume normal liver enzymes mean no significant disease - this is the most dangerous misconception 1
- Do not stop at diagnosing "fatty liver" - you must risk-stratify for fibrosis 1, 2
- Do not order ultrasound to "follow" steatosis - ultrasound cannot assess disease progression or fibrosis 7
- Do not delay metabolic risk factor management - address obesity, diabetes, dyslipidemia aggressively regardless of fibrosis stage